抗C1结构域抗体加速因子VIII清除从而参与小鼠血友病A模型中的抗体致病性
在血友病A小鼠模型中,竞争性抑制因子VIII与血管性血友病因子结合的致病性抗C1和抗C2单克隆抗体加速因子VIII-抗体复合物清除,而在血管性血友病因子缺陷小鼠中该加速清除消失;增加因子VIII剂量可部分纠正抗C1抗体存在时的出血。
要点
- 竞争性抑制血管性血友病因子结合的致病性抗C1和抗C2抗体加速小鼠体内因子VIII清除。
- 不抑制血管性血友病因子结合的抗C1、抗C2和抗A2抗体不加速因子VIII清除。
- 抗C1抗体存在时增加因子VIII输注剂量可部分纠正小鼠出血。
核心结论
- 一部分抑制血管性血友病因子与因子VIII结合的抗体加速因子VIII-抗体复合物清除,这参与抗体致病性。
- 该机制可能解释部分低滴度抑制物血友病A患者尽管接受因子替代治疗仍出现出血表型差异。
研究设计与样本
- 研究为小鼠实验,使用因子VIII基因敲除(FVIII-/-)或因子VIII和血管性血友病因子双基因敲除(FVIII-/-/VWF-/-)小鼠。
- 小鼠输注针对因子VIII C1、C2或A2结构域的抗因子VIII单克隆抗体,随后输注因子VIII。
- 采用断尾出血模型测量失血量,并测定因子VIII活性和因子VIII抗原水平。
主要发现
- 竞争性抑制血管性血友病因子与因子VIII结合的致病性抗C1单克隆抗体在FVIII-/-小鼠中增加因子VIII-抗体复合物清除,但在FVIII-/-/VWF-/-小鼠中未增加。
- 抑制因子VIII与血管性血友病因子结合的致病性抗C2单克隆抗体在FVIII-/-小鼠中增加因子VIII清除。
- 不抑制血管性血友病因子结合的抗C1、抗C2和抗A2单克隆抗体不加速因子VIII清除。
- 在抗C1单克隆抗体存在时,增加因子VIII输注剂量可部分纠正FVIII-/-小鼠的失血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Inhibitor formation remains a challenging complication of hemophilia A care. The Bethesda assay is the primary method used for determining bleeding risk and management. Antibodies that block factor VIII binding to von Willebrand factor can increase FVIII clearance. Antibodies that increase clearance contribute to antibody pathogenicity. SUMMARY: Background The development of neutralizing anti-factor VIII (FVIII) antibodies remains a challenging complication of modern hemophilia A care. In vitro assays are the primary method used for quantifying inhibitor titers, predicting bleeding risk, and determining bleeding management. However, other mechanisms of inhibition are not accounted for in these assays, which may result in discrepancies between the inhibitor titer and clinical bleeding symptoms. Objectives To evaluate FVIII clearance in vivo as a potential mechanism for antibody pathogenicity and to determine whether increased FVIII dosing regimens correct the associated bleeding phenotype. Methods FVIII-/- or FVIII-/- /von Willebrand factor (VWF)-/- mice were infused with anti-FVIII mAbs directed against the FVIII C1, C2 or A2 domains, followed by infusion of FVIII. Blood loss via the tail snip bleeding model, FVIII activity and FVIII antigen levels were subsequently measured. Results Pathogenic anti-C1 mAbs that compete with VWF for FVIII binding increased the clearance of FVIII-mAb complexes in FVIII-/- mice but not in FVIII-/- /VWF-/- mice. Additionally, pathogenic anti-C2 mAbs that inhibit FVIII binding to VWF increased FVIII clearance in FVIII-/- mice. Anti-C1, anti-C2 and anti-A2 mAbs that do not inhibit VWF binding did not accelerate FVIII clearance. Infusion of increased doses of FVIII in the presence of anti-C1 mAbs partially corrected blood loss in FVIII-/- mice. Conclusions A subset of antibodies that inhibit VWF binding to FVIII increase the clearance of FVIII-mAb complexes, which contributes to antibody pathogenicity. This may explain differences in the bleeding phenotype observed despite factor replacement in some patients with hemophilia A and low-titer inhibitors.
引用
- Batsuli G, Ito J, Mercer R, et al. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model. J Thromb Haemost. 2018. PMID: 29981270. doi:10.1111/jth.14233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。